文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Association analysis of intratumoral metabolic heterogeneity assessed by the hottest lesion based on F-FDG PET/CT with immunochemotherapy response in diffuse large B-cell lymphoma.

作者信息

Xin Wenchong, Wang Fei, Gu Weiying, Wang Yuetao

机构信息

Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, China.

Institute of Clinical Translation of Nuclear Medicine and Molecular Imaging, Soochow University, Changzhou, China.

出版信息

Quant Imaging Med Surg. 2025 Sep 1;15(9):8096-8111. doi: 10.21037/qims-2024-2699. Epub 2025 Aug 19.


DOI:10.21037/qims-2024-2699
PMID:40893516
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12397664/
Abstract

BACKGROUND: Intratumoral metabolic heterogeneity (MH) assessed by 18-fluorine fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) has been recognized as a potential marker for chemotherapy resistance in solid tumors. However, research on MH in diffuse large B-cell lymphoma (DLBCL) is limited, and its specific relationship with the response to immunochemotherapy (IC) remains unclear. The objective of this study was to investigate optimal approaches for assessing intratumoral MH, and to analyze the association between PET/CT-based MH and end of treatment (EOT) response to IC in DLBCL. METHODS: This study retrospectively enrolled 304 newly diagnosed patients with DLBCL who underwent baseline F-FDG PET/CT scanning. Intratumoral MH was assessed by the method of the area under the curve of cumulative standardized uptake value (SUV) histogram (AUC-CSH), heterogeneity index (HI), and coefficient of variation (COV) of target lesion. Both univariate and multivariate logistic regression analyses were employed to investigate the association between intratumoral MH and the response to IC at the EOT. After adjusting for confounding factors, we utilized generalized additive model (GAM) and smooth curve fitting to explore potential nonlinear associations, and a binary logistic regression model was used to assess interactions within subgroups. RESULTS: A total of 70 patients (23%) developed primary progressive disease (PPD) at the EOT. Both AUC-CSH and HI were associated with the IC response in DLBCL, with AUC-CSH slightly superior to HI. No significant statistical difference was observed for COV. Univariate regression analysis revealed a significant association between AUC-CSH and the response to IC [odds ratio (OR)/per standard deviation (SD): 0.53; 95% confidence interval (CI): 0.38-0.73; P<0.001]. After adjusting for risk factors, this association remained significant (OR/per SD: 0.58; 95% CI: 0.40-0.85; P=0.006). The GAM indicated a negative linear association between AUC-CSH and the probability of developing PPD, with the top tertile group having the lowest likelihood of developing PPD (14.8%). CONCLUSIONS: In Chinese patients with DLBCL, an approximately negative linear correlation was observed between the AUC-CSH and the probability of developing PPD at the EOT of frontline IC. In simpler terms, as the degree of intratumoral MH increases, the probability of developing PPD also increases.

摘要

相似文献

[1]
Association analysis of intratumoral metabolic heterogeneity assessed by the hottest lesion based on F-FDG PET/CT with immunochemotherapy response in diffuse large B-cell lymphoma.

Quant Imaging Med Surg. 2025-9-1

[2]
123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.

Cochrane Database Syst Rev. 2015-9-29

[3]
PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer.

Cochrane Database Syst Rev. 2014-11-13

[4]
The correlation between preoperative total lesion glycolysis and lymphovascular invasion based on F-FDG PET/CT and its predictive value in primary gastric cancer: a cross-sectional study.

Quant Imaging Med Surg. 2025-9-1

[5]
F-FDG parameters as therapy response predictors in patients with diffuse large B-cell lymphoma: A single centre experience.

Hell J Nucl Med. 2025

[6]
Is 18 F-fluoride PET/CT an Accurate Tool to Diagnose Loosening After Total Joint Arthroplasty?

Clin Orthop Relat Res. 2025-3-1

[7]
Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.

Cochrane Database Syst Rev. 2021-11-9

[8]
Comparison of standardized uptake value and standardized uptake lean body mass metrics in F-fluorodeoxyglucose positron emission tomography for assessing transformation in chronic lymphocytic leukemia and follicular lymphoma.

Quant Imaging Med Surg. 2025-8-1

[9]
Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.

Cochrane Database Syst Rev. 2015-1-9

[10]
Prescription of Controlled Substances: Benefits and Risks

2025-1

本文引用的文献

[1]
Radiomics based on F-FDG PET for predicting treatment response and prognosis in newly diagnosed diffuse large B-cell lymphoma patients: do lesion selection and segmentation methods matter?

Quant Imaging Med Surg. 2025-1-2

[2]
Defining primary refractory large B-cell lymphoma.

Blood Adv. 2024-7-9

[3]
Pretreatment F-FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer.

Cancer Imaging. 2023-9-19

[4]
Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.

J Clin Oncol. 2022-7-20

[5]
Pretreatment F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma.

Ann Nucl Med. 2021-7

[6]
Author Correction: Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma.

Nat Commun. 2020-11-12

[7]
High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma.

Blood Adv. 2020-5-26

[8]
SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.

Blood Adv. 2020-3-24

[9]
Value of Intratumoral Metabolic Heterogeneity and Quantitative F-FDG PET/CT Parameters in Predicting Prognosis for Patients With Cervical Cancer.

AJR Am J Roentgenol. 2020-2-18

[10]
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma.

Cell. 2019-9-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索